A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients With Schizophrenia [EXTENSION OF 700044801]
Latest Information Update: 22 Dec 2021
Price :
$35 *
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Acronyms STEP 210
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 28 Mar 2013 Planned number of patients changed to 300 as reported by Clinical Trials Registry - India.
- 11 Mar 2013 New trial record